1月14日，康泰生物涨0.74%，截至发稿，报16.28元/股，成交4.19亿元，换手率2.84%，总市值181.84亿 元。康泰生物股价已经连续5天上涨，区间累计涨幅6.41%。 资料显示，深圳康泰生物制品股份有限公司位于广东省深圳市南山区粤海街道科技园社区科发路222号 康泰集团大厦，成立日期1992年9月8日，上市日期2017年2月7日，公司主营业务涉及人用疫苗的研发、 生产和销售。主营业务收入构成为：非免疫规划疫苗93.70%，免疫规划疫苗3.71%，其他2.59%。 从基金十大重仓股角度 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 嘉实中证疫苗与生物技术ETF（562860）成立日期2023年2月16日，最新规模2.45亿。今年以来收益 9.28%，同类排名910/5520；近一年收益29.63%，同类排名2947/4203；成立以来亏损25.93%。 嘉实中证疫苗与生物技术ETF（562860）基金经理为周泉希。 截至发稿，周泉希累计任 ...

Core Viewpoint - 康泰生物 reported a revenue increase but a significant decline in net profit for the first half of 2025, indicating potential challenges in profitability despite revenue growth [1] Financial Performance - Total revenue reached 1.392 billion yuan, a year-on-year increase of 15.81% [1] - Net profit attributable to shareholders was 37.53 million yuan, down 77.3% year-on-year [1] - Gross margin decreased to 75.95%, down 9.34% year-on-year [1] - Net margin fell to 2.7%, a decrease of 80.36% year-on-year [1] - Total expenses (selling, administrative, and financial) amounted to 643 million yuan, accounting for 46.22% of revenue, a decrease of 4.77% year-on-year [1] Cash Flow and Assets - Operating cash flow per share increased by 31.42% to 0.07 yuan [1][4] - Cash and cash equivalents decreased by 50.05% due to bank loan repayments and cash dividend distributions [1][2] - Accounts receivable increased by 3.94% to 2.913 billion yuan [1] Investment and R&D - R&D expenditure increased by 41.52% as some projects entered Phase III clinical trials [3] - The company’s investment activities saw a net cash flow increase of 99.23% due to reduced asset-related investments [5] Market Position and Fund Holdings - The company’s return on invested capital (ROIC) was 1.92%, indicating weak capital returns historically [6] - Major funds holding 康泰生物 include 嘉实中证疫苗与生物技术ETF, which increased its holdings [9]

Group 1 - The liquidity of the biotechnology vaccine ETF showed a turnover of 1.21% with a transaction volume of 3.1203 million yuan, and the average daily transaction volume over the past week was 11.3875 million yuan as of May 28 [2] - The biotechnology vaccine ETF closely tracks the CSI Vaccine and Biotechnology Index, which selects no more than 50 companies involved in vaccine research, production, and related biotechnology sectors, reflecting the overall performance of listed companies in this theme [2] - As of April 30, 2025, the top ten weighted stocks in the CSI Vaccine and Biotechnology Index include Wantai Biological Pharmacy, Zhifei Biological Products, and others, accounting for a total of 48.51% of the index [2] Group 2 - The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting will take place from May 30 to June 3 in Chicago, showcasing cutting-edge clinical oncology research and treatment technologies [2] - Guotai Junan Securities recently indicated that the vaccine industry is expected to see a significant increase in inventory levels in both halves of 2024, continuing into the first quarter of 2025, influenced by demand fluctuations and channel inventory adjustments [2] - The overall sentiment in the vaccine sector is under pressure due to factors such as centralized procurement policies and regional political issues [2] Group 3 - Guoxin Securities reported that in April 2025, domestic innovative drug NDA/IND applications remained active, with progress in approvals for vaccine products like the Kangle Guardian trivalent HPV vaccine potentially supporting industry sentiment [3]